Source-grounded facts extracted from Cullinan Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cullinan Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $49.7 million for the first quarter of 2026.
“On May 7, 2026, Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the three months ended March 31, 2026.”
Cullinan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million.
“Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024.”
Thomas Ebeling resigned as Director at Cullinan Therapeutics, Inc..
“Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.”
David Meek was appointed as Class I Director at Cullinan Therapeutics, Inc..
“the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.”
Mary Kay Fenton was appointed as Chief Financial Officer at Cullinan Therapeutics, Inc..
“On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.”
Cullinan Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2024-04-15).
“the Board also approved an amendment and restatement of the Company’s Second Amended and Restated Bylaws solely to reflect the Name Change (as amended and restated, the “ Third Amended and Restated Bylaws ”) effective as of April 15, 2024.”
Cullinan Therapeutics, Inc.: Amended certificate of incorporation to change company name from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc (effective 2024-04-15).
“Effective as of 9:47 A.M., Eastern Time on April 15, 2024, the Company amended its Second Amended and Restated Certificate of Incorporation, as amended (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Cullinan Oncology, Inc.” to “Cullinan Therapeutics, Inc.” (the “ Name Change ”).”
Cullinan Therapeutics, Inc. entered into Stock Purchase Agreement with certain institutional accredited investors valued at $280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a (effective 2024-04-15).
“On April 15, 2024, Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional accredited investors named therein (each, a “ Purchaser ” and collectively, the “ Purchasers ”).”
Cullinan Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On March 14, 2024, Cullinan Oncology, Inc. announced its financial results for the quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.